Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Lawsuit is part of a nationwide strategy by Novo Nordisk to protect its trademark and profits from its blockbuster GLP-1 ...

Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...